Probleme beim Einloggen

Pharma

Dies ist eine aktive Gruppe für alle Experten aus der pharmzeutischen Industrie -- This is an active and large size group for pharma experts

Frank Voggenreiter Experten-Webinar zu SAP S/4HANA Migration in der Pharmaindustrie am 2.Oktober vormerken!
Liebe Gruppenmitglieder,
zum Wochenstart habe ich hier wieder ein spannendes Thema und ein sehr interessantes Webinar für Sie!
Experten-Webinar zu SAP S/4HANA Migration in der Pharmaindustrie
S/4HANA hat sich mittlerweile zu einer vollumfänglichen Entwicklungsplattform gemausert, welche sich auch für die Medikamentenentwicklung, Logistikprozesse und viele weitere Anwendungen in der Pharmaindustrie eignet.
Es gibt (nur) ein Problem: Wie als KMU aus der Pharma- und Medizintechnikbranche auf S/4HANA umsatteln? Die Migration kostet Zeit, Ressourcen und Nerven. Soll die neue Lösung in das bestehende Software- und Architekturkonzept eingegliedert werden (Brownfield-Ansatz) oder ohne infrastrukturelle Beschränkungen ein agiles System modernster Prozesse eingeführt werden (Greenfield-Ansatz)?
Diese und viele weitere wichtige Fragen rund um die Migration zu SAP S/4HANA behandelt das Experten-Webinar: „Vorausschauend: Erfolgreiche Wege in die SAP S/4HANA Migration!“ am 02. Oktober um 
11.00 Uhr (http://www.fujitsu.com/de/webinar/s4hana-1) und 
14.00 Uhr (http://www.fujitsu.com/de/webinar/s4hana-2) . 

Besonderes Augenmerk legt der Experte Hans Thoma, Fachbereichsleiter SAP ERP Logistics bei Fujitsu, auf die wirksame Form des Process Minings. Die Komplettlösung für die Digitalisierung im SAP Umfeld heißt XPressWay und hat sich bereits bei zahlreichen Transformationsprojekten als effektive Methode im gesamten Veränderungsprozess bewährt. Weitere Themen sind:
Orientierung: Wie Unternehmen die Möglichkeiten von S/4HANA erkunden
Vereinfachung: Welche Auswirkungen hat die Migration auf die bestehende Prozesslandschaft
Vorbereitung: Vorstudien als Grundlage für richtige Entscheidung
Benchmark: Welche Prozesse bei Kunden im Fokus stehen
Bewertung: Wie IT-Entscheider den Blick auf das Wesentliche bewahren
Erfahren Sie am 02.Oktober um 11 Uhr und 14 Uhr wie mittelständische Unternehmen ihre Migration erfolgreich verwirklichen können:
Sam George Pain Relief Patches  Market To Reflect Impressive Growth Rate By 2023 | Hisamitsu, Mylan, Johnson & Johnson, Actavis, Lingrui, Teikoku Seiyaku, Sanofi, Novartis
Get Sample PDF Brochure@ https://bit.ly/2Foo8bK
A pain relief patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. Often, this promotes healing to an injured area of the body. An advantage of a transdermal drug delivery route over other types of medication delivery such as oral, topical, intravenous, intramuscular, etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive.
Company Coverage (Sales Revenue, Price, Gross Margin, Main Products etc.):
Hisamitsu, Mylan, Johnson & Johnson, Actavis, Lingrui, Teikoku Seiyaku, Sanofi, Novartis, Qizheng, Endo, Huarun 999, GSK, Haw Par, Nichiban, Mentholatum Company, Laboratoires Genevrier, BLUE-EMU
Billy Waterman Platelet and Plasma Market to Amass Huge Share| $6.5 bn by 2024
The Platelet and Plasma Market is set to exceed USD 6.5 billion by 2024; according to a new research report by Global Market Insights. Rising incidence of haemophilia, thrombocytopenia, autoimmune diseases as well as other infectious and rare disease will serve to be a key driver for the platelet and plasma market growth. According to American Academy of Neurology, plasma can be used for treatment of various neurological conditions. Plasma exchange process involves replacing plasma in a person’s blood. This process can be used for treatment of conditions such as inflammatory dysimmune neuropathies, multiple sclerosis, myasthenia gravis and other disorders will accelerate industry growth during the forecast period.
Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/2737
Platelet is a critical component in blood that assists in blood clotting. The grant is of significance in the platelet and plasma market as it will act a contribution to the development of donor independent, fully functional platelets. The synthetic development of platelets is being encouraged rapidly of late, as unlike platelets sourced from human blood, synthetically developed platelets can last longer, are free from disease and much cheaper which is a major blessing for platelet and plasma industry, as platelets cannot be frozen and have a rather short shelf life.
The military has also received a boost from the U.S. Food and Drug Administration for the treatment of wounds as it has approved the use of an experimental freeze-dried blood plasma. The freeze-dried blood plasma is being hailed as a lifesaver in war zones as such blood plasma does not need refrigeration or thawing which is a big deterrent in the case of regular frozen blood plasma.
Apart from widespread military usage, plasma and platelets form a kind of a basic infrastructure for medical treatments. Right from treatment of severe injury to side effects of cancer treatment, the demand for platelets has been soaring high. Due to the vivid therapeutic and prophylactic applications of platelets, platelets and plasma market size was dominated by the platelet segment in 2017 with a revenue of $3.6 billion, a trend that is expected to be continued over 2018-2024.
According to the American Red Cross, a subject needs platelets every 30 seconds in the United States. The World Health Organization also claims that the shortage of blood and blood products puts millions of lives at risk every year and suppliers have been estimated to provide nearly 835,000 platelet bags of platelets per annum. An ever-growing geriatric population base will encourage governments to not only invigorate blood donation but to develop new technologies that can synthesize platelets without human donors thus augmenting platelet and plasma industry trends further.
The human blood consists of roughly 55% of plasma by volume and has unparalleled healing properties. Plasma derived therapies are being used to treat an expanding list of life threatening disorders adding greater traction to platelet and plasma industry especially with plasma-fractionation techniques being on the rise. As per estimates, platelet and plasma market share from plasma is anticipated to witness a growth rate of 2.1% over 2018-2024. Immunoglobulin, which is used for patients suffering from primary and secondary immunodeficiency disorders and viral and bacterial infections has emerged as a primary driver for platelet and plasma market.
Intravenous immunoglobulin is used in a range of neurological diseases including post-polio syndrome, multiple sclerosis, chronic fatigue syndrome and neuropathic pain. A recent study indicated that intravenous immunoglobulin can have significant value in the treatment of Alzheimer’s. If the study is confirmed, the therapeutic market is expected to expand even further.
Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/2737
U.S. platelet and plasma market dominated industry by holding the global revenue share of over 34% of in 2017. Rising incidences of neurological conditions such as myasthenia gravis, multiple sclerosis and inflammatory dysimmune neuropathies coupled with increasing number of patients suffering from cardiothoracic disorders and orthopedic injuries will serve to be a major impact rendering factor. Moreover, various initiatives undertaken by American Red Cross for creating awareness pertaining to significance of blood donation, availability of advanced healthcare facilities as well as existence of compensated and non-compensated blood donation systems in the U.S. will further fuel the regional growth.
Andreas Grund Klinische Prüfung in der Verkehrsmedizin - Interview (with engl. sub)
Klinische Prüfungen in der Verkehrsmedizin sind etwas Besonderes. Medikamenteneinnahme und das Führen von Fahrzeugen schließen sich aber nicht aus, wenn es die passenden Studien dazu gibt! Ein Thema das immer wichtiger wird.
Hier das Interview, dass ich mit der Expertin Dr. Yvonne Kaußner vom Würzburger Institut für Verkehrswissenschaften (WIVW GmbH) geführt habe.

Moderatoren

Infos zu den Moderatoren

Über die Gruppe "Pharma"

  • Gegründet: 08.10.2004
  • Mitglieder: 18.634
  • Sichtbarkeit: offen
  • Beiträge: 22.832
  • Kommentare: 1.595
  • Marktplatz-Beiträge: 71